Clinical trials: Sadness, open to volunteers
Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
- Conditions
- Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
- Trial name
- NCT07630545
- Testing
- MTX325
- Where
- 18 sites in Australia, France and 2 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mission Therapeutics
Inflammatory Bowel Disease, Colitis, Ulcerative
LMT503 First-in-human SAD, MAD, and FE Study
This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn Disease
- Trial name
- NCT05659953
- Testing
- LMT503
- Where
- Netherlands
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lmito Therapeutics Inc.
Alzheimer s Disease
SAD Study of CGB3002 in Healthy Participants
This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single ascending IV doses of CGB3002 in healthy participants.
- Trial name
- NCT07660341
- Testing
- CGB3002 0.08 mg/kg, CGB3002 0.4 mg/kg, CGB3002 1.2 mg/kg
- Where
- Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- ChainGen Biopharma Ltd
Anxiety Disorders, Panic Disorder
Efficacy of Expectancy Focused Exposure Therapy for Anxiety Disorders
This clinical trial evaluates whether an optimized exposure-based treatment improves long-term outcomes for adults with anxiety disorders.
- Conditions
- Anxiety Disorders, Panic Disorder, Social Anxiety Disorder (SAD), Generalised Anxiety Disorder
- Trial name
- EFE-AD (NCT07753330)
- Testing
- Expectancy Focused Exposure, Anxiety Focused Exposure
- Where
- Chile
- Volunteers
- 203 people
- Sponsor
- University of Chile
Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS)
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
- Trial name
- NCT05995782
- Testing
- FB418
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Healthy
A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled study consisting of SAD and MAD investigation at a single clinical trial center conducted in healthy adult male subjects assessing the safety, tolerability, PK, and…
- Trial name
- NCT07126704
- Testing
- FB-101
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Social Anxiety Disorder (SAD), Social Phobia
Virtual Reality Based Cognitive Behavioral Therapy for Social Anxiety Among Youths in Hong Kong
This randomized controlled trial evaluates the effectiveness of a VR-based CBT intervention for social anxiety-driven depression among Hong Kong youth (ages 15-24).
- Trial name
- NCT06876779
- Testing
- VR intervention
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hong Kong Shue Yan University
Safety, Tolerability
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet
This is a Phase I clinical trial (protocol number: YR-011-B01) sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd., focusing on the novel oral small-molecule drug YR011 (active ingredient: PA032, a Kv1.3 channel…
- Conditions
- Safety, Tolerability, Pharmacokinetics
- Trial name
- NCT07285967
- Testing
- Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Complicated Urinary Tract Infections(cUTI)
Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD)
To evaluate the safety, tolerability and pharmacokinetics of single and multiple intravenous (IV) infusion of TUL108 in healthy participants.
- Trial name
- NCT07719257
- Testing
- TUL108
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Zhuhai United Laboratories Co., Ltd.
Safety, Tolerability
A First-in-Human SAD and MAD Study in HV to Evaluate Oral YR011 Tablet
This is a Phase I clinical trial (protocol number: YR-011-B07) sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd., focusing on the novel oral small-molecule drug YR011 (active ingredient: PA032, a Kv1.3 channel…
- Conditions
- Safety, Tolerability, Pharmacokinetic
- Trial name
- NCT07878481
- Testing
- Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Phase I Study of MT1011 Injection in Healthy Subjects
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects.
- Trial name
- NCT07024160
- Testing
- MT1011
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Social Anxiety Disorder, Body Dysmorphic Disorder
Individual Factors of CBT Underlying Success
The purpose of this study is to understand why some individuals respond fully to cognitive behavioral therapy and others do not, based on multiple sources of data such as neural, neurocognitive, clinical, and self-report data.
- Trial name
- I-FOCUS (NCT06678295)
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Washington
Social Anxiety Disorder (SAD), Attention Bias Modification Treatment (ABMT)
Efficacy of Attention Bias Modification vs. Placebo for Social Anxiety Disorder
This study examines whether a computerized attention-training intervention called attention bias modification (ABM) can reduce symptoms of social anxiety disorder (SAD) in adults, and whether symptom improvement is specifically…
- Conditions
- Social Anxiety Disorder (SAD), Attention Bias Modification Treatment (ABMT), Placebo Effect
- Trial name
- NCT07666776
- Testing
- Dot-Probe Attention Bias Modification (ABM)
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Tel Aviv University
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
Seasonal Affective Disorder (SAD)
Virtual Reality Digital Therapeutics for Seasonal Affective Disorder
Seasonal Affective Disorder (SAD) is commonly treated with bright light therapy. Virtual reality (VR) is an immersive computer-generated environment, which has been used to treat mental health difficulties, such as depression…
- Trial name
- VR-SAD (NCT07161570)
- Testing
- Virtual Reality (VR) Intervention, Light Box (LB) intervention
- Volunteers
- 60 people
- Sponsor
- Anglia Ruskin University
Alpha-1 Antitrypsin Deficiency
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose…
- Trial name
- NCT06405633
- Testing
- WVE-006
- Where
- 9 sites in Australia, Canada and 4 more
- Volunteers
- 48 people
- Sponsor
- Wave Life Sciences USA, Inc.
Idiopathic Pulmonary Fibrosis, Small Airways Disease
Small Airways Disease Functional Assessment in Idiopathic Pulmonary Fibrosis (SWIFT-IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing, and progressive lung disease of unknown cause, whose incidence increases proportionally from the age of 60. It is characterized by a poor prognosis.
- Trial name
- SWIFT-IPF (NCT07312305)
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Milan
Parkinson Disease
First-in-Human Single and Multiple Dose of HL-400
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending…
- Trial name
- NCT06997484
- Testing
- HL-400
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Highlightll Pharmaceutical (USA) LLC
Advanced Solid Tumors
Phase 1 Trial of KH617
KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.
- Trial name
- NCT05667194
- Testing
- KH617
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sichuan Honghe Biotechnology Co., Ltd.
Social Anxiety Disorder (SAD)
The Covideo Study - a Trial of Cognitive Therapy for Social Anxiety Disorder in Youth, Comparing Screen to Office Delivery
The main goal of this clinical trial is to examine screen delivery as an alternative for offering cognitive therapy to youth with social anxiety.
- Trial name
- Covideo (NCT06901128)
- Testing
- cognitive therapy
- Where
- 5 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Sykehuset Innlandet HF